MOL#79863

Introduction
Acetaminophen (APAP) overdose is the leading cause of drug-induced liver injury in the United States (Larson et al., 2005) . The underlying mechanism of APAP hepatotoxicity is thought to be conversion of APAP to N-acetyl-p-benzoquinone imine (NAPQI) which is mediated by members of the cytochrome P450 family, especially CYP2E1 (Nelson, 1990) . NAPQI is detoxified by conjugation with glutathione (GSH) (Mitchell et al., 1973) .
Once the intracellular pool of GSH is depleted, NAPQI covalently modifies cellular proteins resulting in mitochondrial dysfunction and oxidative stress (Hinson et al., 2004; Jaeschke and Bajt, 2006) . Oxidative stress induces cJun-NH 2 -terminal kinase (JNK) activation, which is thought to promote mitochondrial dysfunction and mitochondrial permeability transition (MPT), thereby amplifying oxidative stress, leading to sustained JNK activation which ultimately causes cell death (Chambers and LoGrasso, 2011; Saito et al., 2010) . Indeed, genetic deletion and pharmacological inhibition studies suggest that JNK activation plays a major role in APAP-induced hepatotoxicity (Gunawan et al., 2006; Hanawa et al., 2008; Henderson et al., 2007; Latchoumycandane et al., 2007) . APAP-induced liver injury is mainly a result of necrotic rather than apoptotic cell death (Gujral et al., 2002) . This suggests that JNK may mediate both, necrotic and apoptotic signaling pathways, in hepatocytes. However, JNK activity is also required for hepatocyte proliferation and liver regeneration (Schwabe et al., 2003) , thus targeting JNK directly may ultimately inhibit recovery from APAPinduced liver injury. Therefore, a detailed understanding of the exact mechanism of APAP-induced JNK activation is critical for therapeutic intervention.
This article has not been copyedited and formatted. The final version may differ from this version. (Weston and Davis, 2007) . MAP3K can provide selectivity for activation of JNK by upstream stimuli.
Thus, ASK1 is required for ER stress-and oxidative stress-induced JNK activation (Matsuzawa et al., 2002) , while MLK3 mediates JNK activation in response to saturated free fatty acids (Jaeschke and Davis, 2007; Sharma et al., 2012) . In addition, MAP3K can function either cooperatively or in a temporally sequential manner. For example, TAK1 is essential for the early phase of TNFα-induced JNK activation, while ASK1
plays an important role in the late phase (Sato et al., 2005; Tobiume et al., 2001) .
Similarly, studies using ASK1 KO mice have established a late, ASK1-dependent, and an early ASK1-independent phase of JNK activation following APAP treatment (Nakagawa et al., 2008) . However, the MAP3K that mediates the early phase of APAPinduced JNK activation is unknown. Interestingly, it has been demonstrated that glycogen synthase kinase 3β (GSK3β) is required for the initial phase of APAP-induced 
Animals.
After an overnight fast, male mice (10-12 weeks old) were injected intraperitoneally with 300 mg/kg APAP dissolved in warm saline or saline alone. At various time points mice were sacrificed and blood and livers were harvested. Histology was performed using tissue fixed in 10 % formalin, dehydrated, and embedded in paraffin. Sections were stained with hematoxylin and eosin. The animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Cincinnati.
Biochemical assays. Cell extracts were prepared using Triton lysis buffer (TLB) as described (Jaeschke and Davis, 2007) . Mitochondria were isolated as previously described (Shinohara et al., 2010) . Briefly, livers were excised and homogenized in Hbuffer (210 mM mannitol, 70 mM sucrose, 20 mM Hepes, 0.05 % BSA). The homogenate was centrifuged at 800 x g, for 10 min and the resulting supernatant was centrifuged at 8500 x g for 15 min. The pellet (mitochondrial fraction) was washed once and resuspended in H-buffer. Rac1 activation was analyzed using a Rac1 activation This article has not been copyedited and formatted. The final version may differ from this version. ALT measurements. Plasma ALT was measured using an alanine transaminase activity assay kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's instructions.
GSH measurements. Total liver homogenates were mixed with metaphosphoric acid to prevent GSH autoxidation. GSH levels were measured using a glutathione kit (Cayman Chemical Ann Arbor, MI) according to the manufacturer's instructions.
ROS measurements. Two probes, 2′-, 7′-dichlorofluorescein diacetate (DCFH-DA ) and dihydroethidium (DHE) were used to measure ROS. Hepatic ROS content was measured using DCFH-DA (Sigma Aldrich, St Louis, MO) as previously described (Abubakar et al., 2003) . Briefly, liver homogenates were diluted 100-fold with phosphate-buffered saline (pH 7.4). The homogenates were then loaded with 5 µmol/ml DCFH-DA, and incubated at 37 °C for 30 minutes in dark. Fluorescence was measured using a fluorescence spectrophotometer (Synergy HT, Bio-Tek, Winooski, VT) at This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Role of MLK3 in APAP-induced JNK activation
MLK3 has been shown to mediate ROS-dependent JNK activation in a variety of cell types, such as neurons (Lotharius et al., 2005; Pan et al., 2006) and prostate cancer cells (Hong and Kim, 2007) . Indeed, we found that MLK3 and its upstream activator Rac1 are activated by H 2 O 2 in hepatic cells and are required for oxidative stressinduced JNK activation in primary mouse hepatocytes (data not shown). Since JNK activation is thought to be a result of oxidative stress produced during APAP metabolism and we have established that MLK3 plays a major role in oxidative stressinduced JNK activation, we hypothesized that MLK3 may mediate APAP-induced JNK activation in hepatocytes. Indeed, treatment of primary mouse hepatocytes with APAP induced JNK phosphorylation in WT cells, but not in MLK3 deficient cells (Fig. 1A ). Next we tested if MLK3 is also required for APAP-induced JNK activation in vivo. We found that JNK phosphorylation 1, 3 and 6 hours after APAP treatment was significantly attenuated in MLK3 KO mice (Fig. 1B) , indicating that MLK3 is mediating APAPstimulated JNK activation in vivo. Together these data suggest that MLK3 is required for APAP-induced JNK activation in vitro and in vivo.
Role of MLK3 in APAP-induced hepatotoxicity
Because JNK activation mediates APAP-induced hepatotoxicity (Gunawan et al., 2006; Hanawa et al., 2008; Henderson et al., 2007; Latchoumycandane et al., 2007) , we analyzed cell death in primary mouse hepatocytes. We observed that cells isolated from MLK3 KO mice were partially protected from necrosis caused by treatment with APAP, This article has not been copyedited and formatted. The final version may differ from this version. compared to hepatocytes isolated from WT mice ( Fig. 2A) . This protection was lost upon high doses (≥ 5 mM) of APAP, suggesting a threshold of protection. The protective effect of MLK3 deficiency in vitro suggests that MLK3 may serve an important role in APAP-induced liver injury in vivo. Indeed, loss of MLK3 resulted in significantly lower ALT levels 3h and 6h after APAP treatment (Fig. 2B) . Liver histology showed a significant decrease in necrosis in response to APAP treatment in the absence of MLK3 (Fig. 2C) , consistent with reduced serum ALT levels. Inflammatory cytokines are increased in APAP-induced liver injury and their levels seem to correlate with the severity of the injury (James et al., 2005) . In agreement with a decrease in liver injury, we observed decreased inflammatory cytokine expression in Mlk3 -/-mice treated with APAP compared to WT mice (Fig. 2D ). Together these data suggest that MLK3
mediates, in part, APAP-induced cell death in hepatocytes and plays an important role in APAP-induced liver injury.
Role of RIP1 in APAP-induced hepatotoxicity
APAP-induced liver injury is believed to primarily involve hepatocyte necrosis, and receptor interacting protein 1 (RIP1) is emerging as key regulator of necrotic cell death (reviewed in Vanlangenakker et al., 2012) . Since RIP1 is thought to contribute to JNK activation in response to distinct stimuli (Devin et al., 2003; Seok et al., 2008; Zhang et al., 2007) , we examined the effect of APAP on RIP1 activity in WT and MLK3 KO hepatocytes. We found that loss of MLK3 did not affect APAP-induced RIP1 activity, suggesting that APAP induces RIP1 activation independently of MLK3 (Fig. 3A) .
Similarly, inhibition of RIP1 by necrostatin-1 had no effect on APAP-induced JNK This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3A) . Moreover, treatment of hepatocytes with necrostatin-1, a specific RIP1 inhibitor significantly decreased APAP-induced necrosis in WT hepatocytes and increased the protective effect of MLK3 deficiency in KO hepatocytes (Fig. 3B ).
Together, these data suggest MLK3 and RIP1 act independently in promoting APAPinduced hepatotoxicity.
Role of MLK3 in GSH recovery
To determine if attenuated liver injury is a result of altered APAP metabolism, we examined expression levels of CYP2E1, a protein involved in conversion of APAP to NAPQI (Nelson, 1990) . Expression levels of CYP2E1 were similar in WT and MLK3 KO mice (Fig. 4A) , indicating that loss of MLK3 does not affect NAPQI production. This is consistent with previous studies suggesting that inhibition of JNK does not affect APAP metabolism (Henderson et al., 2007) . Since NAPQI is mainly detoxified by GSH in hepatocytes (Mitchell et al., 1973) and modulation of GSH levels significantly affects APAP hepatotoxicity we analyzed hepatic GSH levels. Basal GSH levels were comparable (WT = 33±2.2, KO = 29±1.9 nmol/mg protein) and the kinetics of APAPinduced GSH depletion were similar in mice of both genotypes (Fig. 4B ). These data are in agreement with unaltered APAP metabolism in MLK3 deficient mice compared to WT mice. However, recovery of hepatic GSH levels at later time points was accelerated in MLK3 deficient mice (Fig. 4B) . To determine the mechanism by which MLK3 deficiency promotes GSH recovery we analyzed expression of glutamate cysteine ligase (GCLc), the catalytic subunit of the rate-limiting enzyme in GSH synthesis, which is known to be regulated by oxidative stress (Franklin et al., 2009 (Fig. 4D) , indicating decreased superoxide production in MLK3 KO hepatocytes. Together these data suggest that MLK3 regulates GSH biosynthesis capacity and mediates ROS formation.
Role of MLK3 in Mcl-1 expression
Recently it has been demonstrated that GSK3β promotes APAP-induced JNK activation (Shinohara et al., 2010) and several studies have suggested that GSK3β induces JNK activation through MLK3 (Mishra et al., 2007; Wang et al., 2010) .
Therefore, we analyzed APAP-induced GSK3β activation in WT and MLK3 deficient mice. Surprisingly, we found that phosphorylation of the GSK3 substrate glycogen synthase (GS) was attenuated in MLK3 KO mice (Fig. 5A ), indicating that MLK3 and subsequent JNK activation are required for APAP-induced activation of
GSK3β. Interestingly, it has been shown that pharmacological inhibition of JNK prevents
This article has not been copyedited and formatted. The final version may differ from this version. However, it is not known which cellular compartment MLK3 signals to JNK activation or whether activated MLK3 also translocates to the mitochondria. More studies will be required to address MLK3 compartmentation in response to oxidative stress.
Interestingly, it was recently proposed that saturated fatty acids induce MLK3 and JNK activation through c-Src (Holzer et al., 2011) and that H 2 O 2 -induced JNK activation involves c-Src (Chen et al., 2001 ). Here we observed that pharmacological inhibition of Src prevents APAP-induced activation of JNK in primary hepatocytes (Supplemental response to distinct stimuli (Devin et al., 2003; Seok et al., 2008; Zhang et al., 2007) . To test the relationship between RIP1 and MLK3 we performed epistatic analysis of the APAP-induced pathway. Loss of MLK3 did not inhibit RIP1 activation and inhibition of RIP1 did not affect MLK3 activity (Fig. 3A) . Moreover, combined inhibition of both pathways lead to increased protection (Fig. 3B) , suggesting that MLK3 and RIP1 are acting through independent mechanisms to promote APAP-induced hepatotoxicity.
We showed that loss of MLK3 significantly attenuates APAP-induced liver injury as determined by decreased necrosis and reduced levels of ALT and inflammatory cytokines ( Fig. 2B-D) . However, the exact mechanism by which MLK3 promotes hepatotoxicity is unclear. Interestingly, we found that GCLc expression is elevated and GSH recovery is accelerated in MLK3 deficient mice (Fig. 4A,B) . Although we did not observe higher basal GSH levels, which is probably due to GSH negative feedback regulation of GCL activity (Franklin et al., 2009) , it could be possible that increased
GCLc expression enhances GSH synthesis in MLK3 KO mice, thus accounting for the decreased APAP-induced liver injury in Mlk3 -/-mice. Indeed, it was demonstrated that overexpression of GCL does not affect basal GSH levels, but enhances GSH resynthesis subsequent to APAP-induced GSH depletion, thereby attenuating druginduced liver injury (Botta et al., 2006) . GCLc levels are regulated transcriptionally, posttranslationally and by degradation, and further studies will be required to address the mechanism by which MLK3 modulates GCLc levels.
Recently it has been shown that GSK3β promotes APAP-induced JNK activation (Shinohara et al., 2010) , and several studies have suggested that GSK3β is required for MLK3-mediated JNK activation, placing MLK3 downstream of GSK3β (Mishra et al., This article has not been copyedited and formatted. The final version may differ from this version. Wang et al., 2010) . Surprisingly, we found that APAP-induced GSK3β activation was inhibited in MLK3 deficient mice (Fig. 5A) ; however, the underlying mechanism is unclear. It has been suggested that positive feedback phosphorylation of MLK3 by JNK may lead to sustained JNK activation (Schachter et al., 2006) , which may result in amplification of oxidative stress. Indeed, we observed decreased ROS production in APAP treated MLK3 KO mice compared to WT mice (Fig. 4C ) and APAP-treated KO hepatocytes (Fig. 4D ). In addition, it has been shown that pharmacological inhibition of JNK activation results in reduced oxidative stress and peroxynitrite formation (Saito et al., 2010) and decreased APAP-induced GSK3β activation (Shinohara et al., 2010) .
Together, these data suggest that MLK3 deficiency may regulate GSK3β indirectly through modulation of ROS production.
A second mechanism by which MLK3 may promote hepatotoxicity is through JNK-mediated regulation of pro-and anti-apoptotic Bcl-2 family members. Recently, it has been demonstrated that Bim deficient mice are protected from APAP-induced liver damage and that APAP strongly induces Bim expression in a JNK-dependent manner (Badmann et al., 2011) . Since we did not observe any differences in BIM expression in MLK3 KO mice compared to WT mice (data not shown), regulation of BIM expression does not seem to account for MLK3-mediated hepatotoxicity. Another possibility is that loss of MLK3 prevents JNK-mediated phosphorylation and inactivation of Bcl-2 and Bcl-X L thereby preventing mitochondrial dysfunction (Latchoumycandane et al., 2007) .
However, Bcl-2 over-expressing mice show higher drug-induced liver injury compared to wild-type mice, questioning the protective role of Bcl-2 in APAP-induced hepatotoxicity (Adams et al., 2001) . Previously, it has been suggested that JNK-mediated Mcl-1
This article has not been copyedited and formatted. The final version may differ from this version. phosphorylation may be one of the mechanisms through which oxidative stress induces cellular damage (Inoshita et al., 2002) , although the role of Mcl-1 in APAP-induced hepatotoxicity has not been established. JNK phosphorylation results in priming of Mcl-1 for phosphorylation by GSK3β and subsequent degradation of the anti-apoptotic protein (Morel et al., 2009) . Indeed, we observed that Mcl-1 is rapidly degraded in WT livers, but not in MLK3 deficient livers (Fig. 5B) . Thus, stabilization of Mcl-1 may be an important mechanism by which MLK3 deficiency protects against APAP-induced hepatocyte death, although further studies will be required to evaluate the role of Mcl-1 in APAP-induced liver injury.
In summary, we show that MLK3 is activated by oxidative stress in hepatocytes and identify MLK3 as MAP3K that mediates the initial phase of APAP-induced JNK activation (Fig. 6 ). Since APAP-induced JNK activation results in amplification of oxidative stress, and oxidative stress plays a critical role in the propagation of cell death and liver injury, our findings suggest that MLK3 could be an important target in APAPinduced liver injury. In addition, we provide evidence that MLK3 regulates GCLc expression, thereby modulating GSH biosynthesis capacity. Together, these studies establish a novel role for MLK3 in APAP-induced liver injury.
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